Recent Publications
PMS2 variant results in loss of ATPase activity without compromising mismatch repair. D'Arcy BM, Arrington J, Weisman J, McClellan SB, Vandana, Yang Z, Deivanayagam C, Blount J, Prakash A. Mol Genet Genomic Med. 2022 Feb 21:e1908. doi: 10.1002/mgg3.1908. Online ahead of print. PMID: 35189042
A specific inhibitor of ALDH1A3 regulates retinoic acid biosynthesis in glioma stem
cells. Li J, Garavaglia S, Ye Z, Moretti A, Belyaeva OV, Beiser A, Ibrahim M, Wilk A, McClellan
S, Klyuyeva AV, Goggans KR, Kedishvili NY, Salter EA, Wierzbicki A, Migaud ME, Mullett
SJ, Yates NA, Camacho CJ, Rizzi M, Sobol RW. Commun Biol. 2021 Dec 21;4(1):1420. doi:
10.1038/s42003-021-02949-7. PMID: 34934174
NAD+ bioavailability mediates PARG inhibition-induced replication arrest, intra S-phase
checkpoint and apoptosis in glioma stem cells. Li J, M Saville K, Ibrahim M, Zeng X, McClellan S, Angajala A, Beiser A, Andrews
JF, Sun M, Koczor CA, Clark J, Hayat F, Makarov MV, Wilk A, Yates NA, Migaud ME, Sobol
RW. NAR Cancer. 2021 Nov 17;3(4):zcab044. doi: 10.1093/narcan/zcab044. eCollection
2021 Dec. PMID: 34806016
Temporal dynamics of base excision/single-strand break repair protein complex assembly/disassembly
are modulated by the PARP/NAD+/SIRT6 axis. Koczor CA, Saville KM, Andrews JF, Clark J, Fang Q, Li J, Al-Rahahleh RQ, Ibrahim
M, McClellan S, Makarov MV, Migaud ME, Sobol RW.Cell Rep. 2021 Nov 2;37(5):109917.
doi: 10.1016/j.celrep.2021.109917. PMID: 34731617
Cancer Immune Checkpoint Inhibitor Therapy and the Gut Microbiota. Frankel AE, Deshmukh S, Reddy A, Lightcap J, Hayes M, McClellan S, Singh S, Rabideau
B, Glover TG, Roberts B, Koh AY. Integr Cancer Ther. 2019 Jan-Dec;18:1534735419846379.
doi: 10.1177/1534735419846379.
DNA Repair Molecular Beacon assay: a platform for real-time functional analysis of
cellular DNA repair capacity. Li J, Svilar D, McClellan S, Kim JH, Ahn EE, Vens C, Wilson DM 3rd, Sobol RW. Oncotarget.
2018 Aug 3;9(60):31719-31743. PMID: 30167090
Immunoregulatory protein B7-H3 regulates cancer stem cell enrichment and drug resistance
through MVP-mediated MEK activation. Liu Z, Zhang W, Phillips JB, Arora R, McClellan S, Li J, Kim JH, Sobol RW, Tan
M. Oncogene. 2018 Aug 6. doi: 10.1038/s41388-018-0407-9. [Epub ahead of print] PMID:30082909
Reprogramming Primary Amniotic Fluid and Membrane Cells to Pluripotency in Xeno-free
Conditions. Slamecka J, Laurini J, Shirley T, Hoerstrup SP, Weber B, Owen L, McClellan S. J
Vis Exp. 2017 Nov 27;(129). doi: 10.3791/56003. PMID:29286443
Induced pluripotent stem cells derived from human amnion in chemically defined conditions. Slamecka J, McClellan S, Wilk A, Laurini J, Manci E, Hoerstrup SP, Weber B, Owen
L. Cell Cycle. 2018;17(3):330-347. doi: 10.1080/15384101.2017.1403690. Epub 2018
Feb 7. PMID:29143560
Immunoregulatory Protein B7-H3 Reprograms Glucose Metabolism in Cancer Cells by ROS-Mediated
Stabilization of HIF1α. Lim S, Liu H, Madeira da Silva L, Arora R, Liu Z, Phillips JB, Schmitt DC, Vu T,
McClellan S, Lin Y, Lin W, Piazza GA, Fodstad O, Tan M. Cancer Res. 2016 Apr 15;76(8):2231-42.
doi: 10.1158/0008-5472.CAN-15-1538. PMID:27197253
Non-integrating episomal plasmid-based reprogramming of human amniotic fluid stem
cells into induced pluripotent stem cells in chemically defined conditions. Slamecka J, Salimova L, McClellan S, van Kelle M, Kehl D, Laurini J, Cinelli P,
Owen L, Hoerstrup SP, Weber B. Cell Cycle. 2016;15(2):234-49. doi: 10.1080/15384101.2015.1121332.
PMID:26654216
p-21 activated kinase 4 (PAK4) maintains stem cell-like phenotypes in pancreatic cancer
cells through activation of STAT3 signaling. Tyagi N, Marimuthu S, Bhardwaj A, Deshmukh SK, Srivastava SK, Singh AP, McClellan
S, Carter JE, Singh S. Cancer Lett. 2016 Jan 28;370(2):260-7. doi: 10.1016/j.canlet.2015.10.028.
PMID:26546043
MicroRNA-345 induces apoptosis in pancreatic cancer cells through potentiation of
caspase-dependent and -independent pathways. Srivastava SK, Bhardwaj A, Arora S, Tyagi N, Singh S, Andrews J, McClellan S, Wang
B, Singh AP.Br J Cancer. 2015 Aug 11;113(4):660-8. doi: 10.1038/bjc.2015.252. PMID:26247574